메뉴 건너뛰기




Volumn 94, Issue 3, 2009, Pages 439-441

Donor lymphocyte infusions in amyloid light chain amyloidosis: Induction of a "graft-versus-plasma cell-dyscrasia effect"

Author keywords

AL amyloidosis; Allogeneic transplantation; Donor lymphocyte infusion; Multiple myelomd and other plasma cell Dyscrasias; Pldsma cell chimerism

Indexed keywords

AMYLOID PROTEIN; DEXAMETHASONE; MELPHALAN;

EID: 62949197887     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.13364     Document Type: Letter
Times cited : (5)

References (12)
  • 1
    • 9144269708 scopus 로고    scopus 로고
    • High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study
    • Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-93.
    • (2004) Ann Intern Med , vol.140 , pp. 85-93
    • Skinner, M.1    Sanchorawala, V.2    Seldin, D.C.3    Dember, L.M.4    Falk, R.H.5    Berk, J.L.6
  • 2
    • 11144358046 scopus 로고    scopus 로고
    • Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation
    • Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004;103:2936-8.
    • (2004) Blood , vol.103 , pp. 2936-2938
    • Palladini, G.1    Perfetti, V.2    Obici, L.3    Caccialanza, R.4    Semino, A.5    Adami, F.6
  • 3
    • 33846256126 scopus 로고    scopus 로고
    • Lenalidomide and dexamethasone in the treatment of AL amyloidosis: Results of a phase 2 trial
    • Sanchorawala V, Wright DC, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007;109:492-6.
    • (2007) Blood , vol.109 , pp. 492-496
    • Sanchorawala, V.1    Wright, D.C.2    Rosenzweig, M.3    Finn, K.T.4    Fennessey, S.5    Zeldis, J.B.6
  • 4
    • 33846258025 scopus 로고    scopus 로고
    • The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
    • Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007;109:465-70.
    • (2007) Blood , vol.109 , pp. 465-470
    • Dispenzieri, A.1    Lacy, M.Q.2    Zeldenrust, S.R.3    Hayman, S.R.4    Kumar, S.K.5    Geyer, S.M.6
  • 6
    • 36348976450 scopus 로고    scopus 로고
    • Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation
    • Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood 2007;110:3561-3.
    • (2007) Blood , vol.110 , pp. 3561-3563
    • Sanchorawala, V.1    Skinner, M.2    Quillen, K.3    Finn, K.T.4    Doros, G.5    Seldin, D.C.6
  • 7
    • 33644757671 scopus 로고    scopus 로고
    • Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: A report from the European Group for Blood and Marrow Transplantation
    • Schonland SO, Lokhorst H, Buzyn A, Leblond V, Hegenbart U, Bandini G, et al. Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation. Blood 2006;107:2578-84.
    • (2006) Blood , vol.107 , pp. 2578-2584
    • Schonland, S.O.1    Lokhorst, H.2    Buzyn, A.3    Leblond, V.4    Hegenbart, U.5    Bandini, G.6
  • 8
    • 0035119772 scopus 로고    scopus 로고
    • Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma
    • Kroger N, Kruger W, Renges H, Zabelina T, Stute N, Jung R, et al. Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma. Br J Haematol 2001;112:421-3.
    • (2001) Br J Haematol , vol.112 , pp. 421-423
    • Kroger, N.1    Kruger, W.2    Renges, H.3    Zabelina, T.4    Stute, N.5    Jung, R.6
  • 9
    • 23244448608 scopus 로고    scopus 로고
    • Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79: 319-28.
    • Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79: 319-28.
  • 10
    • 33646109316 scopus 로고    scopus 로고
    • Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma
    • Kroger N, Zagrivnaja M, Schwartz S, Badbaran A, Zabelina T, Lioznov M, et al. Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma. Exp Hematol 2006;34:688-94.
    • (2006) Exp Hematol , vol.34 , pp. 688-694
    • Kroger, N.1    Zagrivnaja, M.2    Schwartz, S.3    Badbaran, A.4    Zabelina, T.5    Lioznov, M.6
  • 11
    • 34147144964 scopus 로고    scopus 로고
    • Reduced-intensity conditioning for myeloma: Lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning
    • Crawley C, Iacobelli S, Bjorkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007;109:3588-94.
    • (2007) Blood , vol.109 , pp. 3588-3594
    • Crawley, C.1    Iacobelli, S.2    Bjorkstrand, B.3    Apperley, J.F.4    Niederwieser, D.5    Gahrton, G.6
  • 12
    • 47149110690 scopus 로고    scopus 로고
    • Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared to monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability
    • Bochtler T, Hegenbart U, Cremer FW, Heiss C, Benner A, Hose D, et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared to monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. Blood 2008;111:4700-5.
    • (2008) Blood , vol.111 , pp. 4700-4705
    • Bochtler, T.1    Hegenbart, U.2    Cremer, F.W.3    Heiss, C.4    Benner, A.5    Hose, D.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.